Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 9/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7133171 | 1.00 | AKR1C3 (0.55) | AKR1C3APEX1PTGS1PTGS2CES2 | |
| Guanidine SCHEMBL7158194 | 0.89 | AKR1C3 (0.46) | AKR1C3APEX1PTGS1PTGS2TUBB1 | |
| Guanidine SCHEMBL7158197 | 0.89 | AKR1C3 (0.46) | AKR1C3APEX1PTGS1PTGS2TUBB1 | |
| SCHEMBL13391975 | 0.85 | PTGS1 (0.39) | AKR1C3PTGS1PTGS2CES2CES1 | |
| SCHEMBL8058552 | 0.84 | AKR1C3 (0.44) | AKR1C3APEX1PTGS1CES2TBXAS1 | |
| SCHEMBL8058546 | 0.84 | AKR1C3 (0.44) | AKR1C3APEX1PTGS1CES2TBXAS1 | |
| SCHEMBL8746655 | 0.84 | AKR1C3 (0.67) | AKR1C3APEX1TBXAS1 | |
| SCHEMBL8746653 | 0.84 | AKR1C3 (0.67) | AKR1C3APEX1TBXAS1 | |
| SCHEMBL1842530 | 0.82 | AKR1C3 (0.55) | AKR1C3APEX1PTGS2TBXAS1 | |
| SCHEMBL2570881 | 0.82 | AKR1C3 (0.53) | AKR1C3APEX1CES2CES1TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6504057-B2 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-01-07 | — | — | US | disclosed |
| US-20020123529-A1 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | HOECHST AKTIENGESELLSCHAFT | 2002-09-05 | — | — | US | disclosed |
| US-20010020042-A1 | Cardiovascular disorders | HOECHST AKTIENGESELLSCHAFT | 2001-09-06 | — | — | US | disclosed |
| US-5646313-A | PREPARING ENKEPHALINASE INHIBITORS | SOCIETE CIVILE BIOPROJET (FR) | 1997-07-08 | — | — | US | disclosed |
| US-5612371-A | ENZYME INHIBITORS | SOCIETE CIVILE BIOPROJECT (FR) | 1997-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123529-A1 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | TNNI3, SLC5A1, TNNC1 | AKR1C3 613/4885APEX1 2554/4885PTGS1 410/4885 |
| US-20010020042-A1 | Cardiovascular disorders | SLC5A1, SLC9A1, SLC28A1 | AKR1C3 393/4885APEX1 971/4885PTGS1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.